Justin Gainor, MD

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

Justin F. Gainor, MD, director of targeted immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses clinical activity and tolerability of BLU-667 in patients with advanced RET-fusion+ non-small cell lung cancer (NSCLC).